Pharmacogenomics foreword 2020

I would like to wish all our readers a Happy New Year and to introduce you to the 21st volume of Pharmacogenomics.

Looking back over 2019, our most read article was a review of the genetics of clozapine-associated neutropenia by Sophie Legge and James Walters [1]. The authors introduce this rare but clinically important condition and detail the candidate genes and the large-scale genomic studies involved.

The most read research article of the year was a study of pharmacogenomics education in medical and pharmacy schools [2]. The paper looks at survey responses from professional schools on their teaching methods and approaches on pharmacogenomics. It concludes that there have been significant improvements since 2005.

We closed out the year with a themed issue on the innovative area of liquid biopsy. Themed content included three editorials and two reviews looking at the use of this technique in lymphoma, melanoma, and lung and ovarian cancer.

Looking forward to 2020, the editorial team are looking forward to the New Year, with continued publication of the latest cutting-edge research, as well as insightful and topical reviews and perspective papers.

We appreciate all feedback from the pharmacogenomics community regarding the direction of our content, especially suggestions of any priority topics in the field that you feel the journal should cover. We welcome unsolicited research, review and opinion article proposals, amongst others, and would be delighted to hear from you if you are interested in submitting to the journal.

We also encourage you to follow the Pharmacogenomics Twitter account (@pgsjournal) to keep up to date with journal content and PGx news.

I would finally like to take this opportunity to thank our readers, contributing authors, valued Editorial Board members and peer reviewers for their continued support and collaboration as we continue to publish the latest high-impact research. We very much look forward to working with you all over the next year.